



PRODUCT: Rozlytrek™

COMPANY: Genentech, a member of the Roche Group

THERAPEUTIC AREA & INDICATION:

First “tumor agnostic” treatment with biomarkers to specifically target ROS-1 positive metastatic non-small cell lung cancer (NSCLC) as well as other NTRK gene fusion positive solid tumors

ABOUT THE PRODUCT

ROZLYTREK is a small molecule inhibitor of ROS1 and TRK1, 2, and 3, which is indicated for patients with ROS1-positive NSCLC and NTRK fusion-positive solid tumors. ROZLYTREK has demonstrated the ability to penetrate the blood-brain barrier and exert CNS antitumor activity in intracranial models and clinical trials. Strong and durable responses have been observed in patients with and without CNS metastases with both ROS1-positive NSCLC and across various tumor types in patients with NTRK fusion-positive solid tumors. ROZLYTREK represents a valuable precision oncology medicine and an advance for rare and underserved patient populations.